Akanda Retained Earnings (Accumulated Deficit) 2021-2024 | AKAN
Akanda retained earnings (accumulated deficit) from 2021 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
| Akanda Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2023 | $-53 |
| 2022 | $-21 |
| 2021 | $-13 |
| 2020 | $-5 |
| Akanda Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2023-12-31 | $-53 |
| 2023-06-30 | $-27 |
| 2022-12-31 | $-21 |
| 2022-06-30 | $-12 |
| 2021-12-31 | $-13 |
| 2020-12-31 | $-5 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.002B | $0.001B |
| Akanda Corp. provides medical cannabis and wellness platform. The company's initial portfolio includes Bophelo Bioscience & Wellness, a GACP qualified cultivation campus in the Kingdom of Lesotho in Southern Africa and CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK. Akanda Corp. is based in LONDON. | |||